# Secondary Hypertension

Identify secondary hypertension when presentation, treatment resistance, or target-organ injury suggests a remediable cause; confirm true resistance, remove iatrogenic contributors, then prioritize renal disease, primary aldosteronism, obstructive sleep apnea, renovascular disease, and selected endocrine disorders.

**Clinical question:** How should clinicians prioritize evaluation for treatable causes of secondary hypertension in adults?

Updated: 2026-08-24T18:11:07.898139+00:00

## What matters in practice
- In resistant hypertension, screen for primary aldosteronism whether or not hypokalemia is present; it occurs in approximately 20% of resistant-hypertension populations. [1]
- A medication, substance, sodium-exposure, and volume-status review is an early high-yield branch because NSAIDs, sympathomimetics, stimulants, oral contraceptives, corticosteroids, calcineurin inhibitors, alcohol, licorice, and supplements can raise blood pressure. [8]
- Renal parenchymal disease, renovascular disease, obstructive sleep apnea, and primary aldosteronism are common identifiable contributors; pheochromocytoma/paraganglioma, Cushing syndrome, thyroid disease, and coarctation require phenotype-directed testing. [8][12]
- Do not interpret aldosterone-renin or metanephrine testing obtained during severe acute hypertension without accounting for volume depletion, pain, anxiety, medications, kidney failure, and heart failure, which can confound results. [5]
- For confirmed primary aldosteronism, distinguish unilateral from bilateral disease because unilateral aldosterone excess can be treated surgically, whereas bilateral disease is managed with mineralocorticoid receptor antagonism. [1][6][19]

## Identify presentations that warrant a secondary-cause pathway

Escalate beyond routine primary-hypertension management when the phenotype implies a reversible cause or immediate end-organ risk.

Prioritize a secondary-hypertension evaluation in patients younger than 40 years, those with sudden worsening or accelerated hypertension, and those with blood pressure that responds poorly to treatment. Accelerated hypertension with blood pressure above 180/110 mm Hg plus papilledema and/or retinal hemorrhage requires urgent assessment rather than deferred outpatient etiologic testing. [20][21]

For severe blood-pressure elevation, first determine whether acute end-organ damage is present and obtain renal function, electrolytes, bicarbonate, glucose, HbA1c, lipids, complete blood count, clotting studies when microangiopathic hemolytic anemia or disseminated intravascular coagulation is a concern, urine microscopy, urine albumin-to-creatinine ratio, and thyroid function tests. [5]

During a hypertensive crisis, collect endocrine studies selectively and interpret them cautiously. Pressure natriuresis with volume depletion can produce secondary hyperaldosteronism, while medications, pain, anxiety, subarachnoid hemorrhage-related stress, heart failure, and kidney failure can make renin, aldosterone, and metanephrine results unreliable; complete elective secondary-cause testing after stabilization when possible. [5]
- Use immediate plasma and/or urinary metanephrines when the clinical phenotype raises concern for pheochromocytoma or paraganglioma. [5]
- Obtain aldosterone and renin before starting drugs likely to complicate interpretation when primary aldosteronism is under active consideration and the patient is clinically stable enough for testing. [5]
- Do not delay urgent evaluation of suspected pheochromocytoma because it is potentially life-threatening and definitive management is tumor resection. [20]

*Clinical patterns that should redirect evaluation toward secondary hypertension. [8][12][20][21]*

| Clinical trigger | Priority diagnostic direction | Immediate next action |
| --- | --- | --- |
| Hypertension before age 40 years | Broad secondary-cause screen | Evaluate renal, renovascular, endocrine, sleep-related, and drug-induced contributors. [12][21] |
| Accelerated hypertension or BP >180/110 mm Hg with papilledema or retinal hemorrhage | Acute end-organ injury and secondary causes | Urgently assess renal, hematologic, urinary, metabolic, and thyroid abnormalities; stabilize before interpreting confounded endocrine results. [5][20] |
| Resistant hypertension | Primary aldosteronism, renal disease, renovascular disease, obstructive sleep apnea, and medication/substance contributors | Screen for primary aldosteronism regardless of potassium concentration and systematically assess common coexisting causes. [1][3][8] |
| Episodic or clinically suspicious catecholamine-excess phenotype | Pheochromocytoma/paraganglioma | Measure plasma and/or urinary metanephrines and arrange urgent specialty-directed evaluation. [5][20] |

## Exclude modifiable mimics of resistant hypertension

Correct removable pressure-raising exposures and volume contributors before attributing uncontrolled blood pressure to a rare disorder.

Perform a structured reconciliation of prescription drugs, over-the-counter agents, supplements, recreational drugs, alcohol, and dietary exposures. Important causes include NSAIDs including COX-2 inhibitors, sympathomimetic decongestants and anorectics, cocaine, amphetamines, oral contraceptive hormones, adrenal steroid hormones, erythropoietin, cyclosporine, tacrolimus, licorice-containing products, and supplements containing ginseng, yohimbine, ma huang, or bitter orange. [8]

Assess sodium exposure, extracellular-volume status, kidney disease, and adequacy of diuretic therapy. Excess sodium intake, volume retention from kidney disease, and inadequate diuresis can maintain apparent resistant hypertension and should be corrected in parallel with etiologic testing. [8]

Actively assess obesity, diabetes, and obstructive sleep apnea in resistant hypertension. Obstructive sleep apnea is a common secondary cause associated with resistant hypertension, and its coexistence does not exclude renal, renovascular, or endocrine causes. [2][3][8]
- Document NSAID, decongestant, stimulant, hormonal, corticosteroid, calcineurin-inhibitor, erythropoietin, and supplement exposure at each resistant-hypertension assessment. [8]
- Treat volume overload and optimize diuretic strategy before labeling blood pressure as pharmacologically refractory. [8]
- Use sleep-symptom assessment and formal sleep evaluation when obstructive sleep apnea is suspected clinically. [2][8]

*Reversible contributors to address before expanding low-pretest-probability endocrine testing. [8]*

| Contributor | Examples | Clinical action |
| --- | --- | --- |
| Medication-related blood-pressure elevation | NSAIDs, COX-2 inhibitors, sympathomimetics, oral contraceptives, corticosteroids, erythropoietin, cyclosporine, tacrolimus [8] | Stop, substitute, or minimize the implicated exposure when clinically feasible; reassess blood pressure response. [8] |
| Substance or supplement exposure | Cocaine, amphetamines, excess alcohol, licorice, ginseng, yohimbine, ma huang, bitter orange [8] | Obtain a nonjudgmental exposure history and discontinue the causative product. [8] |
| Sodium and volume excess | Excess sodium intake, kidney-disease-associated volume retention, inadequate diuretic therapy [8] | Correct sodium and volume contributors while evaluating kidney disease. [8] |
| Sleep-disordered breathing | Obstructive sleep apnea [2][8] | Pursue sleep-focused evaluation when symptoms or resistant hypertension indicate risk. [2][8] |

## Match testing to the most actionable etiologic branch

Use clinical phenotype and initial kidney, urine, endocrine, and sleep findings to sequence confirmatory testing.

Renal parenchymal disease is the most common medical cause of secondary hypertension in resistant-hypertension evaluations. Abnormal renal function, urine microscopy, or urine albumin-to-creatinine ratio should direct the next diagnostic step toward kidney disease rather than an isolated endocrine workup. [5][8]

Consider renovascular disease when the overall clinical setting suggests renal arterial disease, particularly in resistant hypertension. Renal artery stenosis is among the common identifiable causes in this setting; renal artery and kidney imaging should be directed by clinical suspicion rather than used as a universal screen. [5][8]

Primary aldosteronism is a high-priority, treatment-changing diagnosis. It occurs in approximately 5% to 10% of all hypertension and about 20% of resistant hypertension, and the 2025 AHA/ACC guideline recommends screening adults with resistant hypertension regardless of whether hypokalemia is present. [1]

Use the plasma aldosterone-to-renin ratio as the screening test for primary aldosteronism in patients with hypertension, including those without hypokalemia. A positive screen generally requires confirmation of inappropriate aldosterone secretion with a suppression test such as saline infusion or fludrocortisone suppression before subtype-directed management. [6][24]
- If primary aldosteronism is confirmed, obtain adrenal imaging for anatomy but do not rely on CT or MRI alone to establish functional laterality; adrenal vein sampling is the reference standard for localization. [6]
- In confirmed primary aldosteronism with an adrenal adenoma, perform dexamethasone suppression testing to assess for cortisol co-secretion. [19]
- Order plasma and/or urinary metanephrines for suspected pheochromocytoma/paraganglioma; pursue Cushing syndrome testing only when the clinical phenotype supports it. [5]
- Use thyroid testing as part of severe-hypertension assessment and evaluate overt hypo- or hyperthyroidism as potential contributors when results are abnormal. [5][14]

### Primary aldosteronism

Primary aldosteronism should not be limited to the classic hypokalemic phenotype. Bilateral adrenal hyperplasia accounts for approximately two-thirds of cases, while about one-third have unilateral aldosterone overproduction from an aldosterone-producing adenoma, less often unilateral hyperplasia, and rarely adrenal carcinoma. [1]

Refer for multidisciplinary endocrine, radiology, and surgical evaluation once biochemical testing supports primary aldosteronism and a patient is a potential procedural candidate. The key management decision is functional laterality: unilateral disease supports laparoscopic adrenalectomy, whereas bilateral disease supports medical mineralocorticoid receptor antagonism. [6][19]
- Use aldosterone, renin, and potassium testing to screen for primary aldosteronism in hypertension under the 2025 Endocrine Society recommendation. [18][19]
- Screen patients with resistant hypertension even if serum potassium is normal. [1]
- Recognize that targeted treatment is associated with improved kidney and cardiovascular outcomes. [1]

*Etiology-directed diagnostic branches for secondary hypertension. [5][6][8][12][19][24]*

| Etiologic branch | Clues or initial findings | Focused test or next step | Management implication |
| --- | --- | --- | --- |
| Renal parenchymal disease | Abnormal renal function, urine microscopy, or urine albumin-to-creatinine ratio [5][8] | Direct evaluation to kidney disease after abnormal initial renal and urine testing. [5][8] | Address kidney-associated volume retention and optimize diuretic therapy. [8] |
| Renovascular disease | Resistant hypertension with a clinical setting suggestive of renal arterial disease [3][8] | Obtain renal artery and kidney imaging when suspicion is sufficient. [5] | Define renovascular disease within a specialist-directed treatment plan. [1][3] |
| Primary aldosteronism | Resistant hypertension, with or without hypokalemia [1][24] | Screen with aldosterone-to-renin ratio; confirm inappropriate secretion with saline infusion or fludrocortisone suppression when indicated. [6][24] | Use adrenal vein sampling for functional localization when subtype classification will direct treatment. [6] |
| Obstructive sleep apnea | Resistant hypertension or sleep-symptom phenotype [2][8] | Perform sleep-focused clinical assessment and formal evaluation when indicated. [2] | Treat sleep-disordered breathing as a contributing cause while evaluating coexisting secondary etiologies. [3][8] |
| Pheochromocytoma/paraganglioma | Clinical suspicion for catecholamine excess [5][20] | Measure plasma and/or urinary metanephrines. [5] | Arrange urgent specialty evaluation; definitive treatment is surgical tumor removal. [20] |
| Cushing syndrome or thyroid disease | Compatible clinical phenotype or abnormal thyroid testing [5][14] | Test for Cushing syndrome when clinically suspected; obtain thyroid function tests in severe hypertension. [5] | Treat the identified endocrine disorder rather than escalating antihypertensive therapy alone. [12][14] |

## Link diagnosis to definitive treatment and follow-up

The value of testing is highest when the result changes a durable intervention, not simply the antihypertensive drug count.

For primary aldosteronism, treatment selection follows subtype. Laparoscopic adrenalectomy is the preferred definitive therapy for unilateral aldosterone-producing adenoma and often cures or markedly improves hypertension; bilateral disease is treated medically with mineralocorticoid receptor antagonists. The Endocrine Society suggests spironolactone over alternative medical therapy for patients receiving primary-aldosteronism-specific treatment. [6][19]

Use specialist referral early for suspected primary aldosteronism, pheochromocytoma/paraganglioma, Cushing syndrome, or renovascular hypertension because testing and treatment require technical interpretation and, in selected cases, specialized procedures. [1][20]

Follow treatment response using blood pressure, serum potassium when mineralocorticoid excess or antagonism is relevant, and kidney function during management of kidney disease or mineralocorticoid receptor antagonist therapy. In primary aldosteronism, reassess blood-pressure control and biochemical abnormalities after medical therapy or adrenalectomy because cure is not universal even after treatment of unilateral disease. [6][19]
- Use adrenal vein sampling rather than anatomical imaging alone when accurate lateralization is required before unilateral adrenalectomy. [6]
- Add dexamethasone suppression testing when primary aldosteronism coexists with an adrenal adenoma. [19]
- Refer suspected pheochromocytoma/paraganglioma promptly for specialty evaluation and surgical planning after biochemical assessment. [5][20]

*Treatment decisions that depend on etiologic confirmation. [1][6][19][20]*

| Confirmed diagnosis | Definitive or disease-specific strategy | Key decision point |
| --- | --- | --- |
| Unilateral primary aldosteronism | Laparoscopic adrenalectomy [6] | Establish functional laterality with adrenal vein sampling when subtype classification will determine surgery. [6] |
| Bilateral primary aldosteronism | Medical mineralocorticoid receptor antagonism; spironolactone is suggested by the Endocrine Society. [19] | Use medical therapy when aldosterone excess is bilateral rather than surgically lateralized. [6][19] |
| Pheochromocytoma/paraganglioma | Surgical tumor removal is definitive treatment. [20] | Proceed through urgent specialist investigation after clinical suspicion and metanephrine testing. [5][20] |
| Drug- or substance-induced hypertension | Withdrawal, substitution, or reduction of the causative exposure [8] | Reassess blood pressure after eliminating the identified contributor. [8] |

## References
1. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
2. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hyp.0000000000000066
3. Resistant Hypertension: Detection, Evaluation, and ... — www.ahajournals.org — https://www.ahajournals.org/doi/pdf/10.1161/HYP.0000000000000084
4. Resistant Hypertension: Diagnosis, Evaluation, and ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hypertensionaha.108.189141
5. Management of hypertensive crisis: British and Irish ... — www.nature.com — https://www.nature.com/articles/s41371-022-00776-9
6. Primary Aldosteronism Diagnosis and Management | Endocrinology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/primary-aldosteronism-diagnosis-and-management
7. Recognize, Monitor, Treat: A Comprehensive Approach to Improving Resistant Hypertension Care — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jaccas.2025.105991
8. Resistant Hypertension: An Overview of Evaluation and Treatment — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2008.08.036
9. Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2026.102596
10. Cardiac Phenotypes in Secondary Hypertension: JACC State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2022.08.714
11. Spectrum of Hyperaldosteronism, Opportunities for Diagnosis — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/aimcc.2024.0383
12. Evaluations of secondary hypertension and laboratory data in the elderly population — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0929664624003401
13. Evaluation and Management of Secondary Hypertension — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S0025712521001632
14. Renal Hypertension - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/renal-hypertension
15. Review Diagnosis and treatment of primary aldosteronism — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2213858721002102
16. Diagnosing endocrine hypertension: a practical approach — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/nep.13078
17. Diagnosis and treatment of primary aldosteronism: ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/joim.12831
18. Endocrine Society guideline calls for increased screening for common cause of high blood pressure | Endocrine Society — www.endocrine.org — https://www.endocrine.org/news-and-advocacy/news-room/2025/endocrine-society-guideline-calls-for-increased-screening-for-common-cause-of-high-blood-pressure
19. Primary Aldosteronism — www.endocrine.org — https://www.endocrine.org/clinical-practice-guidelines/primary-aldosteronism-2
20. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL ... — www.nice.org.uk — https://www.nice.org.uk/guidance/qs28/documents/hypertension-briefing-paper2
21. Prevalence and Risk Factors for Secondary Hypertension ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.124.22753
22. Primary Aldosteronism | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.033597
23. Clinical Management of Primary Aldosteronism: An Update — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.124.22642
24. Renin Ratio Cutoff for Primary Aldosteronism | Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.116.08407

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.